Human haemoglobin(Sangart)(Human haemoglobin(Sangart))

概要

基本信息

药物类型

蛋白类药物

别名

Human haemoglobin (Sangart)、MalPEGHb、MP4

+ [5]

靶点-

作用方式-

作用机制

氧载体

治疗领域

心血管疾病肿瘤泌尿生殖系统疾病+ [1]

在研适应症-

非在研适应症

手术失血慢性肢体威胁性缺血重度下肢缺血+ [3]

原研机构

Sangart, Inc.

在研机构-

非在研机构

Sangart, Inc.

权益机构-

最高研发阶段终止临床3期

首次获批日期-

最高研发阶段(中国)-

特殊审评-

登录后查看时间轴

关联

6

项与 Human haemoglobin(Sangart) 相关的临床试验

EUCTR2009-013115-35-DE

/ Not yet recruitingN/A

A multi-center, randomized, double-blind, controlled dose-finding study to evaluate the safety and efficacy of MP4OX treatment plus standard of care in severely injured trauma patients with lactic acidosis due to hemorrhagic shock

开始日期2010-02-25

申办/合作机构

Sangart, Inc.

NCT00633659

/ Completed临床2期

A Phase II Study of Hemospan® Versus Voluven® to Evaluate Vascular Resistance and Forearm Blood Flow, and to Assess Local Skin Blood Flow and Tissue Oxygenation in the Ischemic Foot of Patients With Chronic Critical Limb Ischemia

The purpose of this study is to evaluate the effects of Hemospan infusion on vascular reactivity, regional perfusion and oxygenation of ischemic tissue in patients with chronic critical lower limb ischemia.

开始日期2007-09-01

申办/合作机构

Sangart, Inc.

NCT00420277

/ Completed临床3期

A Randomized, Double-Blind, Phase III Study of the Efficacy and Safety of an Oxygen-Carrying Plasma Expander, Hemospan®, Compared With Voluven® toTreat Hypotension in Patients Undergoing Primary Hip Arthroplasty With Spinal Anesthesia

The purpose of this study is to determine whether Hemospan is superior to Voluven for treatment of hypotensive episodes during the perioperative period (from induction of spinal anesthesia until 6 hours after skin closure), and for reducing the incidence of operative and postoperative complications including organ dysfunction and failure until follow-up at one month following surgery. An independent Data Safety Monitoring Board (DSMB) will periodically evaluate the safety data collected during this trial

开始日期2007-02-01

申办/合作机构

Sangart, Inc.

100 项与 Human haemoglobin(Sangart) 相关的临床结果

登录后查看更多信息

100 项与 Human haemoglobin(Sangart) 相关的转化医学

登录后查看更多信息

100 项与 Human haemoglobin(Sangart) 相关的专利（医药）

登录后查看更多信息

68

项与 Human haemoglobin(Sangart) 相关的文献（医药）

2025-01-07·Translational Animal Science

Effects of coating on recovery of Escherichia coli-derived phytase under different steam pelleting conditions

Article

作者: Xie, Jingjing ; Zhang, Hu ; Cao, Ning ; Zhao, Feng ; Wang, Yuming ; Qi, Bingqian

Abstract:

The objective of this study was to evaluate the effect of coating on the recovery rate (RR) of phytase activity during the steam conditioning-pelleting (SCP) process. A split-plot design was employed, with phytases assigned to the main plot and two conditioning temperatures (75 or 85 °C) assigned to the subplot. The whole plot was repeated four times. In Exp. 1, six phytases were analyzed, including an uncoated phytase (NP) NP1 (NP1), two coated phytases (CP) CP1 and CP2 derived from NP1, and three commercial phytases (MP) MP1-MP3. In Exp. 2, coating technology was refined based on the results of Exp. 1, and nine phytases were analyzed, including an NP2, five coated phytases CP3-CP7 derived from NP2, and three commercial phytases MP4-MP6. Phytase activity after the steam-conditioning, pelleting, and cooling process was analyzed, and the RR of phytase activity was calculated for each process. In Exp. 1, significant interactions between phytase and conditioning temperature on the RR of phytase activity were observed (P < 0.05). The RR of CP1 and CP2 did not differ from that of NP1. Commercial phytase MP3 exhibited a lower RR than the other four phytases when conditioned at 75 °C (P < 0.05). Except for MP3, the RR of phytases decreased as the conditioning temperature increased (P < 0.05). In Exp. 2, the RR of phytase decreased as the conditioning temperature increased from 75 to 85 °C (P < 0.05). Compared with NP2, the RR increased, and the loss rate of activity for all five coated phytase (CP3-CP7) decreased after the conditioning process (P < 0.05). Commercial phytase MP4 and MP6 had comparable RR to NP2, while MP5 exhibited a comparable RR to CP3-CP7. In conclusion, the coating technology used in Exp. 1 did not increase the RR of phytase during the pelleting process, whereas the improved coating process employed in Exp. 2 effectively increased the thermostability of phytase.

2024-11-01·INTERNATIONAL JOURNAL OF BIOLOGICAL MACROMOLECULES

Effects of in vitro simulated digestion and fecal fermentation on the structure and regulating the glucose and lipid activity of a polysaccharide from Mori Folium

Article

作者: Han, Lifeng ; Zhu, Tongtong ; Wang, Ying ; Fu, Zhifei ; Liu, Erwei ; Zhang, Han ; Zhang, Lingyu ; Zhang, Boli

Mori folium, as a homologous drug-food, has hypoglycemic and lipid-lowering activity. Polysaccharides are the main bioactive ingredient of the Mori folium that exhibit diverse biological activities. In this study, a homogeneous polysaccharide (MP4) was purified and characterized from Mori folium. The changes of MP4 affected by saliva, simulated gastrointestinal juice, and human fecal fermentation, including physicochemical property or its bioactivity, were systematically investigated. Meanwhile, the influence of fermentation on the bioactivity were evaluated. The results showed that the backbone of MP4 is mainly composed of →4)-α-D-GalpA-(1→ residues. The molecular weight, the levels of reducing sugar content and free monosaccharides of MP4 exhibited no significant differences indicating that gastrointestinal digestion has a minimal effect on the physicochemical characteristics of MP4. However, during in vitro gut microbiota fermentation, MP4 are significantly degraded and utilized by gut microbiota, showing increased the production of short-chain fatty acids, notably acetic acid and propionic acid. The relative abundance of beneficial bacteria such as Bacteroidetes and Actinobacteria were significantly increased, whereas the levels of pathogenic bacteria such as Fusobacteria and Megamonas were significantly decreased, which changed the composition of the gut microbiota. The Firmicutes/Bacteroides ratio was also decreased significantly. Interestingly, after in vitro fermentation, the α-glucosidase inhibitory activity was increased, the lipase inhibitory activity and cholesterol adsorption activity was decreased. Correlation analysis showed that the relative abundance of some bacteria was significantly correlated with the bioactivities. These results provide a basis for the development of Mori folium polysaccharides as functional probiotic products.

2024-03-01·Food research international (Ottawa, Ont.)

Comprehensive analysis of flavor formation mechanisms in the mechanized preparation Cantonese soy sauce koji using absolute quantitative metabolomics and microbiomics approaches

Article

作者: Zhao, Chi ; Lin, Weifeng ; Zhang, Yuxiang ; Li, Weixin ; Lin, Jiayi ; Wu, Huizhen ; Luo, Lixin

Based on the widespread application and under-research of mechanized preparation Cantonese soy sauce koji (MP), absolute quantitative approaches were utilized to systematically analyze the flavor formation mechanism in MP. The results indicated that the enzyme activities increased greatly during MP fermentation, and 4 organic acids, 15 amino acids, and 2 volatiles were identified as significantly different flavor actives. The flavor parameters of MP4 were basically identical to those of MP5. Furthermore, microorganisms were dominated by Staphylococcus, Weissella, and Aspergillus in MP, and their biomass demonstrated an increasing trend. A precise enumeration of microorganisms exposed the inaccuracy of relative quantitative data. Concurrently, Staphylococcus and Aspergillus were positively correlated with numerous enzymes and flavor compounds, and targeted strains for enhancing MP quality. The flavor formation network comprises pathways including carbohydrate metabolism, lipid metabolism and oxidation, and protein degradation and amino acid metabolism. In summary, the fermentation period of MP can be substantially shortened without compromising the product quality. These findings lay the groundwork for refining parameters in modern production processes.

100 项与 Human haemoglobin(Sangart) 相关的药物交易

登录后查看更多信息

研发状态

10 条进展最快的记录,

登录

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
低血压	临床3期	比利时	Sangart, Inc.	2007-02-01
低血压	临床3期	捷克	Sangart, Inc.	2007-02-01
低血压	临床3期	荷兰	Sangart, Inc.	2007-02-01
低血压	临床3期	波兰	Sangart, Inc.	2007-02-01
低血压	临床3期	瑞典	Sangart, Inc.	2007-02-01
低血压	临床3期	英国	Sangart, Inc.	2007-02-01
缺血	临床3期	比利时	Sangart, Inc.	2007-02-01
缺血	临床3期	捷克	Sangart, Inc.	2007-02-01
缺血	临床3期	荷兰	Sangart, Inc.	2007-02-01
缺血	临床3期	波兰	Sangart, Inc.	2007-02-01